There is currently a national shortage of sodium citrate (“blue top”) blood collection tubes used for coagulation testing as a result of unprecedented demand, in part due to COVID-19 surges, vaccine and treatment development. This is anticipated to last through August 2021. Please take this into consideration when ordering coagulation testing (i.e. Protime, aPTT, Fibrinogen, D-dimer, Lupus Screens, Factor Assays, Mixing Studies, von Willebrand testing, etc.).
Here are additional steps you can take to help:
• Eliminate collection of extra blue top tubes
• Discontinue standing orders for coagulation tests, when possible
• Avoid the use of coagulation tubes as discard tubes
• Please refrain from ordering Lupus Screens ( LAB478) when patients are actively taking non vitamin K antagonists, including apixaban, dabigatran, and rivaroxaban. They have a significant impact on clot-based coagulation testing. It is best to carry these tests out prior to drug administration or during a trough setting.
• Reduce cancelled specimens by making sure to collect specimens correctly by using the lab catalog for specimen collection instructions.
Thank you for your help during this exceptional time.
If you have any questions or concerns, please use the “Contact Us” link above.
Effective Wednesday, December 18, 2019, Cystatin C will change from a sendout reference test performed by Mayo Clinic Laboratories to an in-house test performed by Spectrum Health Regional Laboratory. This test will be performed in the Toxicology Laboratory and will include a new reference range (please see link in Test Information below).
Questions may be directed to Toxicology via the “contact us” link above.
Cystatin C – Epic Code #LAB3226, Interface #11631, CPT #82610
The most conclusive evidence for using thyroid peroxidase antibody (TPO) is predictive in nature when evaluating possible subclinical hypothyroidism. If this test is positive, hypothyroidism occurs at a rate of 4.3% per year versus 2.6% per year when the antibody is negative. While this scenario does not cover all clinical indications for ordering TPO, there is no definitive evidence that repeat TPO testing provides additional information.1
Based on this information the ordering of TPO within Spectrum Health is being modified. If the test is ordered more than once on a patient, a screen will appear in EPIC indicating the following: “This test should typically only be resulted once per lifetime. The duplicate checking indicates that this patient has already had this testing performed. Please see chart review for results.” This is not a “hard stop” but providers will need to click “Continue” to proceed with the order.
Please join us in welcoming our new pathologists to Spectrum Health Regional Laboratory!
Spectrum Health Regional Laboratory is adjusting the Microalbumin Analytic Measurement Range (AMR) in order to standardize within the Spectrum Health Hospital System and to align with our vendor’s (Roche Diagnostics) recommendations. The lower limit of the Microalbumin AMR will be changed from 0.50 to 1.20 mg/dL. Results below the AMR will now be reported as < 1.20 mg/dL. The upper limit will remain the same at 444.00 mg/dL.